Reaction
Lymph Node Pain reporting signals
As of the last recalculation, Lymph Node Pain appears in 1,839 FAERS reports alongside 32 co-occurring drug terms. The strongest observed disproportionality signal is PYRAZINAMIDE (PRR 10.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pyrazinamide | 9 | 10.9 | 10.9 |
| Hydrocortisone Sodium Succinate | 9 | 10.9 | 10.9 |
| Abacavir Sulfate | 9 | 10.5 | 10.5 |
| Prochlorperazine | 25 | 10.3 | 10.3 |
| Felodipine Extended-Release Tablets | 10 | 10.0 | 10.0 |
| Felodipine | 10 | 10.0 | 10.0 |
| Filgrastim | 28 | 8.5 | 8.5 |
| Acalabrutinib | 9 | 8.4 | 8.4 |
| Ibrutinib | 52 | 7.5 | 7.5 |
| Pegvaliase-Pqpz | 5 | 6.9 | 6.9 |
| Efavirenz | 6 | 6.1 | 6.1 |
| Fludarabine Phosphate | 21 | 6.1 | 6.1 |
| Cladribine | 5 | 5.9 | 5.9 |
| Ofatumumab | 17 | 5.8 | 5.8 |
| Vincristine Sulfate | 15 | 5.8 | 5.8 |
| Ocrelizumab | 31 | 5.7 | 5.7 |
| Desoximetasone | 9 | 5.4 | 5.4 |
| Venetoclax | 24 | 4.5 | 4.5 |
| Galcanezumab-Gnlm | 12 | 4.3 | 4.3 |
| Peginterferon Beta-1A | 5 | 4.3 | 4.3 |
| Ozanimod Hydrochloride | 3 | 4.1 | 4.1 |
| Tirzepatide | 57 | 4.1 | 4.1 |
| Abemaciclib | 7 | 4.0 | 4.0 |
| Rucaparib | 3 | 3.8 | 3.9 |
| Bosutinib | 3 | 3.8 | 3.8 |
| Botulinum Toxin Type A | 4 | 3.7 | 3.7 |
| Pegfilgrastim | 31 | 3.6 | 3.6 |
| Fremanezumab-Vfrm | 3 | 3.0 | 3.0 |
| Abaloparatide | 7 | 2.7 | 2.7 |
| Nemolizumab-Ilto | 3 | 2.7 | 2.7 |
| Sarilumab | 6 | 2.6 | 2.6 |
| Nirmatrelvir And Ritonavir | 10 | 2.1 | 2.1 |